Sujal Shah
2018
In 2018, Sujal Shah earned a total compensation of $1.9M as President and Chief Executive Officer at Cymabay Therapeutics, a 62% decrease compared to previous year.
Compensation breakdown
| Bonus | $271,078 |
|---|---|
| Option Awards | $1,211,685 |
| Salary | $451,796 |
| Other | $3,458 |
| Total | $1,938,017 |
Shah received $1.2M in option awards, accounting for 63% of the total pay in 2018.
Shah also received $271.1K in bonus, $451.8K in salary and $3.5K in other compensation.
Rankings
In 2018, Sujal Shah's compensation ranked 5,908th out of 14,244 executives tracked by ExecPay. In other words, Shah earned more than 58.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,908 out of 14,244 | 59th |
Division Manufacturing | 2,246 out of 5,765 | 61st |
Major group Chemicals And Allied Products | 836 out of 2,128 | 61st |
Industry group Drugs | 698 out of 1,817 | 62nd |
Industry Pharmaceutical Preparations | 542 out of 1,391 | 61st |
Source: SEC filing on April 26, 2019.
Shah's colleagues
We found four more compensation records of executives who worked with Sujal Shah at Cymabay Therapeutics in 2018.
News
Cymabay Therapeutics CEO Sujal Shah's 2022 pay rises 16% to $2.6M
April 19, 2023
Cymabay Therapeutics CEO Sujal Shah's 2021 pay slips 16% to $2.2M
April 26, 2022
Cymabay Therapeutics CEO Sujal Shah's 2019 pay jumps 32% to $2.6M
May 15, 2020
Cymabay Therapeutics General Counsel Paul Quinlan receives $3M in 2018
April 26, 2019